We are a fully integrated pure-play biologics Contract Development and Manufacturing Organization (CDMO), offering the complete spectrum of services, from cell line technology transfer to clinical and commercial manufacturing with capabilities to convert drug substance into stable formulations and fill and finish formats. We have proven technical expertise in microbial, mammalian, viral vectors, and various other technology platforms with world-class cGMP manufacturing facilities that offer high-quality services for your global programs.
State-of-the-art Facilities
Our three state-of-the-art facilities, with ~85,000 sqm of area house process development laboratories, scale-up, and manufacturing areas for mammalian, microbial and other modalities. Our highly automated facilities provide global services for products based on Monoclonal antibodies, Fusion proteins, Conjugation factors, Vaccines, Cell-free protein expression platforms, DNA adjuvants/plasmids, RNA products, Cell and gene therapy, and all other types of biologics, biosimilars and vaccines. Our agility in building capacities, increasing accuracy, efficiency and speed at every stage of process development and manufacturing processes is unparalleled.
Large Capacities
Stelis, over the years, has built a robust CDMO platform. We offer large drug substance capacities of over 48,000L across various modalities and drug product capacities exceeding 400 million units per annum. We have the capabilities to deliver your projects from clinical to commercialization with best-in-class facilities capable of delivering any scale of production volumes with agility to expand capacities at industry-leading speed.
With 48,000L of drug substance capacities across multiple modalities, we are one of the largest CDMOs in the Asia-Pacific (APAC) region.
Global Quality
Our experienced quality and regulatory personnel help us meet the highest global quality standards, ensure compliance and guide our clients through the regulatory approval. Our large-scale commercial use facilities were designed with consultation from international regulatory agencies, including the USFDA, and a holistic and systematic approach to building and sustaining the Stelis Quality Culture. In addition to several partner audits , we were recently inspected by the European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA), Australia. We expect United States Food and Drug Administration (USFDA) inspection in 2022*.
*EMA: Accreditation received for Unit 1 and Unit 2 biologics facilities
*TGA: Inspection pending closure
*FDA: Pre-approval inspection scheduled in the near term
Strong Technical Acumen
Quality and efficiency are at the core of our delivery principles and when coupled with our diverse and deep experience in biopharmaceutical development and manufacturing, our highly talented scientific and technical teams can deliver your program outcomes expeditiously – bringing your asset to market sooner. It starts with a leadership team that understands what it takes to deliver highly complex scientific programs for our clients that count on us to meet our commitments on-time and in-full.
Our Vision
Our vision is to be globally recognized as the most trusted and reliable biopharmaceutical CDMO.
Our Mission
Our mission is to reliably deliver our clients’ biopharmaceutical programs on-time and in-full.
Our Values
Integrity
Operate with the highest degree of integrity and transparency with no compromises at all. By integrity, we mean our people, products and processes display integrity always.
Collaboration
Collaborate with team members and colleagues to deliver synergy and excellence in all activities, actions and decisions, such that we deliver high customer advocacy.
Efficiency
Display entrepreneurial zeal towards work, render high quality services and deliver safe and superior products efficiently.
Integrity
We adhere to ethical
practices and maintain
transparency in our conduct,
fostering a culture of trust &
integrity in the organisation
Competency
We develop and effectively
apply our knowledge, abilities
and skills to successfully and
consistently deliver desired
outcomes
Efficiency
We are agile and
collaborative to
deliver quicker and
better results
Key Differentiators
Collaborative
We work side-by-side with our clients as true partners, collaborating and closely communicating every step of the way.
Agile
We have the proven ability to rapidly adjust or expand to meet the evolving needs and demands of our clients.
Compliant
We have established and will sustain a Stelis Quality Culture that enables us to always meet global quality and regulatory standards.
Meet the Leadership Team
Our leadership team brings deep industry experience, including having successfully delivered complex biologics programs for many of the industry’s most renowned companies, across all modalities. Collectively, they lead Stelis to successfully deliver client programs in totality as assured.
Neeraj Sharma
Managing Director
Anurag Bhagania
Chief Financial Officer
Frank Ternes
Chief Business Officer
Prateek Gupta
Head of Process Development and MSAT
Our Investors
In 2021, Stelis concluded $195M (~INR 1,500 Crore) of fundraising cumulatively through Series B and Series C. Fundraising was led by the family office of the founders/promoter and other marquee investors, including TPG Growth, Route One, and Think Investments.
Strides Pharma Science Limited (Strides)
Tenshi Life Sciences
TPG Growth
Think Investments
Mankekar Family
Our Investors
In 2021, Stelis concluded $195M (~INR 1,500 Crore) of fundraising cumulatively through Series B and Series C. Fundraising was led by the family office of the founders/promoter and other marquee investors, including TPG Growth, Route One, and Think Investments.
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.
Headquartered in Bangalore, India, Tenshi is the family office of Arun Kumar (Founder of Strides group and Stelis). Tenshi has investments across different business domains, that include active pharmaceutical ingredients, affordable biopharma, aseptic fill-finish, technology-led complex formulation platforms, and vertically integrated women’s healthcare. As core philosophy, Tenshi thrives on its entrepreneurial mindset, with its decisions pivoting on a scarcity-led theme.
TPG Growth is the middle market and growth equity investment platform of TPG, the global alternative asset firm. With approximately $13.5B of assets under its management, TPG Growth targets investments in various industries and geographies. TPG Growth has deep sector knowledge, operational resources, and global experience to drive value creation and help companies reach their full potential. The firm is backed by the resources of TPG, which has more than $94B of assets under management.
“Think” is a $3B investment firm headquartered in San Francisco with an additional presence in Mumbai. Think invests globally in public and private companies with a multi-year time horizon. The firm specializes in backing technology-led early-stage businesses and partners with high-quality management teams looking to build differentiated businesses with high returns on invested capital.
Mankekar family office represents the business investments of Shivanand Shankar Mankekar, a former full-time professor at Mumbai’s Jamnalal Bajaj Institute of Management Studies and a seasoned investor with a significant holding in Indian equities.
Board of Directors
Aditya Puri
Non-Executive Director & Chairperson
Vineeta Rai
Independent Director
Arun Kumar
Founder and Non-Executive Director
Ankur Thadani
Non-Executive Director
Mahadevan N
Non-Executive Director
AK Viswanathan
Independent Director
P R Kannan
CFO and Executive Director
Current Investors
Our Corporate Governance
Our History
With an investment of over $300M to create comprehensive capabilities and adequate capacities, Stelis Biopharma is uniquely positioned as the front-runner in the CDMO market.
Beginning
Stelis Biopharma Limited (Stelis) is the biopharmaceutical division of Strides Pharma Science Limited (Strides), a global pharmaceutical company headquartered in Bangalore, India. Strides provides affordable high quality generic medicines in over 100 countries supported by its global manufacturing footprint spanning eight facilities spread across four continents, including multiple sites with Stringent Regulatory Authority approvals such as USFDA, EMA and others. To know more about Strides, www.strides.com
Developing industry-leading infrastructure
From 2015 onwards, Stelis has built a fully integrated commercial bio-manufacturing facility for both drug substance and drug product spread over 19,000 sqm.
In partnership with Merck Life Sciences, Stelis set up a cGMP scale-up facility alongside of the Process Development Laboratory.
Stelis initially enhanced the manufacturing capacities by commissioning and qualifying a multi-platform and multi-product drug substance microbial facility for commercial manufacturing.
The drug substance and drug product capacities were further augmented through the commissioning of a large facility for drug substance manufacturing supporting multiple modalities and very high-speed fill & finish capabilities.
A global biopharmaceutical CDMO with a complete and integrated end-to-end offering
Today, Stelis Biopharma is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), with a complete and integrated end-to-end offering. World-class process development and manufacturing infrastructure for both drug substance (mammalian and microbial-based therapeutic proteins, lentivirus, adenovirus and retrovirus manufacturing, cell and gene therapy, RNA products and adherent and suspension-based processes) and drug product (lyophilized vials, liquid vials, pre-filled syringes, cartridges and devices). Our three state-of-the-art facilities are staffed by highly talented professionals. As the most agile CDMO in the industry, Stelis Biopharma is a trusted CDMO partner of choice.
Beginning
Stelis Biopharma Limited (Stelis) is the biopharmaceutical division of Strides Pharma Science Limited (Strides), a global pharmaceutical company headquartered in Bangalore, India. Strides provides affordable high quality generic medicines in over 100 countries supported by its global manufacturing footprint spanning eight facilities spread across four continents, including multiple sites with Stringent Regulatory Authority approvals such as USFDA, EMA and others. To know more about Strides, www.strides.com
Developing industry-leading infrastructure
From 2015 onwards, Stelis has built a fully integrated commercial bio-manufacturing facility for both drug substance and drug product spread over 19,000 sqm.
In partnership with Merck Life Sciences, Stelis set up a cGMP scale-up facility alongside of the Process Development Laboratory.
Stelis initially enhanced the manufacturing capacities by commissioning and qualifying a multi-platform and multi-product drug substance microbial facility for commercial manufacturing.
The drug substance and drug product capacities were further augmented through the commissioning of a large facility for drug substance manufacturing supporting multiple modalities and very high-speed fill & finish capabilities.
A global biopharmaceutical CDMO with a complete and integrated end-to-end offering
Today, Stelis Biopharma is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), with a complete and integrated end-to-end offering. World-class process development and manufacturing infrastructure for both drug substance (mammalian and microbial-based therapeutic proteins, lentivirus, adenovirus and retrovirus manufacturing, cell and gene therapy, RNA products and adherent and suspension-based processes) and drug product (lyophilized vials, liquid vials, pre-filled syringes, cartridges and devices). Our three state-of-the-art facilities are staffed by highly talented professionals. As the most agile CDMO in the industry, Stelis Biopharma is a trusted CDMO partner of choice.